Search

Search Constraints

You searched for: Author/Creator Andersen, Scott W.

Search Results

2. [P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD). (1st July 2017)

4. Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P‐gp Substrate. (18th December 2019)

5. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Issue 11 (13th October 2020)

6. Delayed‐start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Issue 2 (25th July 2015)

7. Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease. Issue 1 (10th August 2018)

8. DT‐01‐04: LANABECESTAT: BASELINE CHARACTERISTICS OF PARTICIPANTS RANDOMIZED IN THE PHASE 2/3 AMARANTH STUDY. (1st July 2006)